Free tool
Healthcare stocks
We cover 51 companies in the Healthcare sector. The median market value in the group is $2.10B. Across the group, the median move over the past trading day is 0.00%. 96% of the 51 with a 200-day average trade above it. Price change over the past year runs from −38.7% to +282.0% across the middle 80 percent of the group, with a median of +61.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
51 of 2,203 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% |
| DWTX | Dogwood Therapeutics, Inc. | $90.42M | Micro cap | −42.80% |
| INCR | InterCure Ltd. | $69.65M | Micro cap | +265.03% |
| INMB | INmune Bio Inc. | $67.86M | Micro cap | +19.56% |
| PRPO | Precipio, Inc. | $54.43M | Micro cap | +99.25% |
| HOWL | Werewolf Therapeutics, Inc. | $48.05M | Micro cap | −25.65% |
| HBIO | Harvard Bioscience, Inc. | $34.83M | Micro cap | +44.34% |
| KYNB | Kyntra Bio, Inc. | $32.82M | Micro cap | −22.66% |
| TXMD | TherapeuticsMD, Inc. | $26.39M | Micro cap | +103.57% |
| BFRI | Biofrontera Inc. | $22.72M | Micro cap | +77.91% |
| PMI | Picard Medical, Inc. | $20.13M | Micro cap | +113.51% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8660.74% |
| LEXX | Lexaria Bioscience Corp. | $18.24M | Micro cap | +1146.05% |
| BCDA | BioCardia, Inc. | $18.02M | Micro cap | −38.66% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −25.57% |
| APRE | Aprea Therapeutics, Inc. | $12.34M | Micro cap | −38.75% |
| LUCY | Lucyd, Inc | $9.73M | Micro cap | −42.05% |
| FBLG | FibroBiologics, Inc. | $9.39M | Micro cap | −88.25% |
| XBIO | Xenetic Biosciences, Inc. | $9.04M | Micro cap | +35.92% |
| SKYE | Skye Bioscience, Inc. | $8.92M | Micro cap | −41.62% |
| CURX | Curanex Pharmaceuticals Inc | $7.21M | Micro cap | −1.29% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +211.51% |
| BIAF | bioAffinity Technologies, Inc. | $3.02M | Micro cap | −31.59% |
| SCNI | Scinai Immunotherapeutics Ltd. | $1.48M | Micro cap | +93.92% |
| APM | Aptorum Group Ltd | $570.06K | Micro cap | +273.78% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.